Curated News
By: NewsRamp Editorial Staff
June 08, 2026
Lifordi's ADC LFD-200 Shows Promise in Phase 1 RA Trial
TLDR
- Lifordi's LFD-200 ADC avoids cortisol suppression, potentially offering a safer alternative to standard glucocorticoids.
- LFD-200 delivers a glucocorticoid directly to immune cells via subcutaneous injection, showing dose-responsive anti-inflammatory activity without systemic toxicity.
- LFD-200 could improve quality of life for rheumatoid arthritis patients by reducing side effects like cortisol suppression.
- Lifordi presented first-in-human data for LFD-200 at EULAR 2026, showing anti-inflammatory effects without affecting cortisol levels.
Impact - Why it Matters
This news matters because it represents a potential breakthrough in treating autoimmune diseases like rheumatoid arthritis. Current glucocorticoid therapies, while effective, come with serious systemic side effects such as adrenal suppression and metabolic issues. LFD-200's targeted delivery to immune cells could offer similar or better efficacy without these toxicities, improving patient quality of life. If successful, this ADC platform could be adapted for other inflammatory conditions, expanding treatment options. For patients suffering from RA and related disorders, this development brings hope for safer, more effective therapies that directly address the root cause without compromising overall health.
Summary
Lifordi Immunotherapeutics, Inc., a clinical-stage biotechnology company, announced promising first-in-human data for LFD-200, a novel subcutaneous antibody-drug conjugate (ADC) designed to deliver a potent glucocorticoid directly to immune cells for treating autoimmune and inflammatory disorders. Presented at EULAR 2026 in London, the Phase 1 study in healthy participants showed that LFD-200 was well tolerated and exhibited dose-responsive anti-inflammatory activity without suppressing serum cortisol levels—a key marker of systemic glucocorticoid toxicity. This is a significant advancement as current glucocorticoid therapies often cause severe side effects due to systemic exposure. Dosing has begun in patients with moderate to severe rheumatoid arthritis (RA), with results expected by year-end 2026. For full details, including images and bios, click here.
Lifordi is pioneering the use of ADC technology beyond oncology, applying it to autoimmune diseases. The company’s platform can also deliver other payloads, such as antisense oligonucleotides (ASOs), siRNA, and small molecules. Backed by prominent investors including ARCH Venture Partners, Atlas Venture, 5AM Ventures, and Sanofi Ventures, Lifordi aims to transform treatment paradigms for immune and inflammatory conditions. The Phase 1 data for LFD-200 represents a critical step toward a safer, more targeted therapy for RA and potentially other diseases. The company continues to enroll patients in the RA cohort, and the upcoming data will be pivotal for further development. For more information, visit www.lifordi.com and follow on LinkedIn.
Source Statement
This curated news summary relied on content disributed by Reportable. Read the original source here, Lifordi's ADC LFD-200 Shows Promise in Phase 1 RA Trial
